According to @QCompounding, Olema Pharmaceuticals (OLMA) delivered a 348.8% year-to-date gain over the last year, flagging the stock as a high-momentum trade for market participants, source: @QCompounding on X, Jan 8, 2026 https://twitter.com/QCompounding/status/2009250121976815735. The post states Olema is a clinical-stage biotech focused on targeted therapies for breast cancer, source: @QCompounding on X, Jan 8, 2026 https://twitter.com/QCompounding/status/2009250121976815735. The source characterizes Olema as a potential next big cancer drug success, highlighting why investor attention has increased, source: @QCompounding on X, Jan 8, 2026 https://twitter.com/QCompounding/status/2009250121976815735. It also notes investors achieved a 348.8% one-year return, underscoring the strong trend profile relevant to momentum strategies, source: @QCompounding on X, Jan 8, 2026 https://twitter.com/QCompounding/status/2009250121976815735. The post provides no direct linkage to cryptocurrency markets or tokens, and no crypto exposure is cited, source: @QCompounding on X, Jan 8, 2026 https://twitter.com/QCompounding/status/2009250121976815735.